TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05658146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 2
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days
Study: NCT06409104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
Study: NCT05658146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten Capsule 3
Description: Specified dose on specified days
Study: NCT06313229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement 6 months after ridge augmentation
Description: the deficient ridge was grafted first followed by implant placement after 6-monthes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement Simultaneously with ridge augmentation
Description: the deficient ridge was grafted and followed by implant placement simultaneously
Study: NCT05884996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF training
Description: Resistance training with elastic bands in diagonals of PNF
Study: NCT04689178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation letter + GP reminder
Description: 40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation letter
Description: 40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
Study: NCT05365191

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Near infrared fluorescence navigated sentinel lymph node mapping
Description: Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
Study: NCT05594511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle-energy mandibular technique
Description: A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham technique
Description: A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
Study: NCT05487677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBrace Augmentation
Description: During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
Study: NCT06017076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral energy drinks
Description: Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Warming matress
Description: From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
Study: NCT05495672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local treatment
Description: Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany).
Study: NCT05487677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Repair with Sutures
Description: During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
Study: NCT06498440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% Eye Drops
Description: Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops
Description: Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
Study: NCT05127915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adient absorbable filter + best practice VTE prophylaxis
Description: Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adient absorbable filter + best practice VTE prophylaxis
Description: Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: best practice VTE prophylaxis
Description: Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
Study: NCT05460481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Penpulimab
Description: Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
Study: NCT06552936

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diode Laser 980 nm.
Description: A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diode Laser 980 nm.
Description: A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diode Laser 980 nm.
Description: A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diode Laser 980 nm.
Description: A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
Study: NCT05862974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 30min duration
Study: NCT05570136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Exercise
Description: Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education
Description: In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
Study: NCT04631367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kukaa Salama: mHealth intervention
Description: Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face Mask + Soap
Description: Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
Study: NCT05759481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is administered starting at surgery induction and ending at skin closure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered starting at surgery induction and ending at skin closure
Study: NCT06004440

Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Subjects will under a planned procedure with the Ion Endoluminal System
Study: NCT05888766

Intervention type: DRUG
Intervention: Rimegepant 75 milligrams
Description: At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
Study: NCT04566679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dibuzin
Description: 2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
Study: NCT05157230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
Study: NCT06115824

Intervention type: DRUG
Intervention: Orelabrutinib
Description: Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
Study: NCT04709250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective nerve block
Description: the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine
Study: NCT05757518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryosauna
Description: The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
Study: NCT05051527

Intervention type: DRUG
Intervention: Legalon® 140 mg
Description: Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
Study: NCT06503133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Birth preparation training
Description: Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth preparation training
Description: Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal yoga practice
Description: Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
Study: NCT05211492

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients are asked to fill in an online questionnaire concerning their postoperative pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients are asked to fill in an online questionnaire concerning their postoperative pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients are asked to fill in an online questionnaire concerning their postoperative pain.
Study: NCT05412693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional orthosis
Description: See arm descriptions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast immobilization
Description: See arm descriptions
Study: NCT06186622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Administered orally.
Study: NCT04773964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET642
Description: MET642 active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET642
Description: MET642 active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06416878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brief ES at the time of decompression for cauda equina syndrome
Description: In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brief ES to facilitate mcturition/removal of catheter
Description: In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
Study: NCT05092828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine Injection
Description: In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Relieving
Description: Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
Study: NCT06169696

Intervention type: DEVICE
Group type: OTHER
Intervention: Intervention/Treatment
Description: Non-invasive EEG headband device
Study: NCT05669963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactoferrin
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactoferrin
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.